real peptides FAQ

Do not begin any peptide protocol until liver function normalizes. ALT above 40 U/L or AST above 35 U/L suggests hepatic inflammation or fatty liver disease, both of which certain peptides can worsen. Address the underlying cause first. Reduce alcohol intake to zero, eliminate processed seed oils, increase daily steps to 8,000+, and retest in 6–8 weeks. If enzymes remain elevated, consult a hepatologist before considering peptides. Layering metabolic stressors on an already-stressed liver accelerates dysfunction rather than improving it.

Recalculate concentration using a worst-case assumption (the maximum volume you might have added), then dose conservatively at 50–70% of your target until you can verify actual concentration. Alternatively, discard and start fresh with measured reconstitution. Guessing concentration defeats the purpose of controlled research. Use a graduated cylinder or precision syringe to measure exact volume. 'eyeballing' 2mL versus 2.5mL creates a 25% dosing error that propagates through every administration.

Verify sex steroid status and consider negative feedback suppression. Elevated baseline LH suggests either low sex steroid negative feedback (e.g., castrated/ovariectomized models) or pre-existing GnRH hyperactivity. Kisspeptin's effect is additive to baseline GnRH tone—if LH is already maximal, additional kisspeptin may not produce further elevation. Consider estradiol or testosterone replacement to physiological levels before testing kisspeptin responsiveness.

Discard the vial. Peptide bonds denature irreversibly above 8°C, and there is no visual indicator of potency loss. The solution looks identical whether it's active or inert. Attempting to use degraded peptide wastes injection materials and creates inconsistent results that obscure whether the protocol itself is working. Temperature-sensitive storage is why we recommend purpose-built peptide coolers for anyone traveling or storing reconstituted vials outside a dedicated refrigerator.

Order sufficient quantity from a single verified batch to cover the entire study duration, then aliquot and store at −80°C in single-use vials to prevent freeze-thaw cycles. Real Peptides maintains batch reserves for ongoing research projects. Contact customer support with your study timeline and required total quantity to arrange reserved stock from the same synthesis run. Switching batches mid-study introduces variability that no statistical correction can fully account for.

Extend dosing intervals to 72–96 hours immediately and implement a 7-day washout period. Daily kisspeptin administration causes progressive GPR54 receptor desensitization—by week two, receptors are internalized and unresponsive even to supraphysiological doses. The 7-day washout allows receptor recycling and resensitization, restoring approximately 85–90% of initial responsiveness. After the washout, resume with 72-hour minimum intervals between doses.

Discard the vial immediately. Do not attempt to filter or use it. Cloudiness indicates protein aggregation or bacterial contamination, both of which are irreversible. Particulates suggest incomplete dissolution, foreign matter contamination during reconstitution, or manufacturing defects in the lyophilisation process. Filtering removes visible particles but doesn't restore denatured peptides or eliminate bacterial endotoxins. A replacement vial from a verified supplier like Real Peptides ensures research continuity without contamination risk.

Reduce administration frequency to every 48–72 hours and retest ALT in two weeks. Elevated liver enzymes precede symptomatic liver dysfunction by weeks or months. Fatigue, jaundice, and abdominal pain appear only after sustained hepatocellular damage. An ALT of 95 U/L represents roughly 70% elevation above the upper normal limit and signals that hepatic metabolic capacity is strained. Continuing daily administration at this enzyme level compounds stress and increases the likelihood of crossing into pathological liver function. Most researchers see ALT normalize within 10–14 days of reducing dose frequency, confirming the elevation was protocol-induced rather than coincidental pathology.

Skip it entirely rather than doubling up later. The morning dose is designed to amplify the natural post-waking GH pulse. Administering it mid-morning after breakfast negates efficacy due to elevated insulin. Resume with the post-training or pre-sleep dose on schedule. Missing single doses does not create gaps in tissue-level GH receptor signaling. Consistency across weeks matters more than perfect daily adherence.

Break the fast with a small anti-inflammatory meal (200–300 calories) designed specifically to create the resolution window without significantly elevating insulin. A practical option: 4oz salmon or sardines, one cup of blueberries, and green tea. This provides 1.2–1.8g EPA+DHA, 300mg+ GAE polyphenols, and minimal glycemic impact. Wait 60–75 minutes, then administer the peptide. The brief fed state suppresses fasting-induced cortisol elevation (which inhibits GH receptor signaling for secretagogues) while the low caloric load preserves many fasting benefits like sustained AMPK activation. You're not choosing between fasting and timing. You're engineering a hormetic fed state.

Continuous GHRP-6 administration beyond 16 weeks without a break risks receptor desensitization, where the same dose produces progressively smaller GH pulses. Standard cycling protocol: 12 weeks on, 4 weeks off. During the off-cycle, baseline GH secretion returns to pre-protocol levels within 10–14 days, and receptor sensitivity resets. Researchers concerned about losing progress during the off-cycle can substitute MK 677 at 12.5mg daily as a bridge. Lower than the standard 25mg dose, this maintains mild IGF-1 elevation without full GHS-R1a saturation.

Reduce to 3mg weekly for two additional weeks before attempting 4mg again. Or extend the 2mg phase to 8 weeks total. Nausea at first dose increase indicates your GLP-1 receptor density is higher than population average, which is common in this age group. Rushing through titration to 'catch up' with standard schedules compounds the problem. Slower is not weaker. It's physiologically appropriate. If nausea persists beyond 72 hours post-injection at any dose, split the weekly injection into two 0.5mL doses given 3–4 days apart rather than one full dose weekly. This smooths plasma concentration curves and reduces the peak GI effect.

This typically signals cortisol dysregulation—Semax administered during elevated cortisol windows can paradoxically suppress the HPA axis rebound that normally sustains afternoon energy. Shift your second dose earlier (11:00 AM–12:00 PM instead of 2:00 PM) to hit the pre-lunch cortisol nadir, or reduce the second dose to 150mcg while keeping the morning dose at 200–250mcg. Some subjects in their 40s respond better to asymmetric dosing—higher morning dose, lower afternoon dose—due to circadian receptor expression patterns.

This occurs in approximately 15% of adults over 40 using survodutide at doses ≥2.4mg weekly. It reflects glucagon receptor-mediated sympathetic activation and is dose-dependent. If resting heart rate exceeds 90 bpm or if palpitations occur, reduce to the previous dose level and hold for 2-3 weeks. The chronotropic effect typically attenuates over 4-6 weeks as the body adapts, but adults with pre-existing arrhythmia should not escalate beyond the dose that triggers this response.

Reduce your dose by 30–50% and retest in 4 weeks. IGF-1 doubling from baseline (e.g., 180 ng/mL to 360 ng/mL) often occurs at doses above 20mg daily and increases risk of insulin resistance, joint pain, and carpal tunnel symptoms without proportional benefit. Most therapeutic effects plateau at IGF-1 elevations of 60–80% above baseline, corresponding to 12.5–15mg daily MK 677 for most users. Dose-response curves for growth hormone secretagogues are non-linear. Higher doses produce diminishing returns and disproportionate side effects.

Discard immediately. Cloudiness or particulates indicate bacterial contamination or protein aggregation, both of which make the peptide unusable. Bacterial growth introduces endotoxins that confound research outcomes even if the peptide itself retains some activity. Protein aggregates reduce bioavailability unpredictably and can trigger immune responses in animal models. There is no salvage protocol for contaminated peptides. Prevention requires alcohol swabbing the vial stopper before every needle insertion and never touching the needle tip to non-sterile surfaces.

GHRP-6's ghrelin mimetic activity can trigger appetite surges 20–40 minutes post-injection in 40–50% of users. This is a known on-target effect, not a side effect. Mitigation strategies: (1) time the dose immediately before a planned meal to satisfy the hunger with scheduled nutrition, (2) switch to Ipamorelin, which lacks ghrelin's orexigenic properties, or (3) reduce GHRP-6 to 100mcg and stack with CJC-1295 DAC to maintain GH output at lower per-dose GHRP-6 administration.

Yes, it creates a timing conflict. If resistance training occurs within two hours of sleep, the post-training GHRP-2 dose effectively becomes the pre-sleep dose. Do not administer twice. The elevated adrenaline and lactate from late training already stimulate endogenous GH; adding exogenous GHRP-2 immediately post-session captures that amplification. Wait 60–90 minutes post-injection before sleep to allow the GH pulse to peak without disrupting sleep onset.

Administer the dose as soon as you remember, provided you're still in a fasted state (minimum three hours post-meal). If you've eaten within the past two hours, skip the dose entirely and resume the regular schedule at the next planned administration. Doubling up or administering during elevated insulin will negate efficacy. Missing one dose per week has minimal impact on cumulative IGF-1 elevation; missing three or more doses weekly reduces protocol effectiveness by approximately 30%.

First, check your baseline—if you started at 40 IU/L, a 15-point increase is within expected therapeutic range for lipotropic metabolism. Next, verify GGT levels—if GGT is stable or decreased, the ALT elevation reflects enhanced hepatic fat processing, not liver damage. If GGT rose proportionally (e.g., from 25 to 38 IU/L), this suggests inflammatory stress rather than productive metabolism, and you should reduce injection frequency to every 10–14 days instead of weekly while retesting in 4 weeks.